2 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Byron Lam: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Choroideremia Gene Therapy Clinical Trial Injection of AAV2-REP1 (10e11 vg) - Choroideremia | Phase 2 | Completed | Byron Lam | 6 | 2015-09-01 | 2019-07-29 |
| Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med), injection of scAAV2-P1ND4v2 2.4 X10e10vg (High) - Leber's Hereditary Optic Neuropathy | Phase 1 | Completed | Byron Lam | 28 | 2014-07-14 | 2025-06-05 |
Choroideremia (1) · Optic Atrophy, Hereditary, Leber (1)
United States (2)
PMID 30194931, PMID 24398093, PMID 24457989, PMID 25342621, PMID 26606867, PMID 27631475, PMID 28647203, PMID 35271811, PMID 35344016, PMID 37716450, PMID 38117686
U10EY023558 (1)